EDIT vs VERX
EDIT: A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL receptor upregulation. VERX: Vertex automates and governs transaction-based indirect tax compliance across 195 countries for enterprises, embedded into their commerce systems to handle real-time tax calculation, reporting, and digital transmission to authorities.
Side-by-side fundamentals
| Metric | EDIT | VERX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.78 | $11.05 | |
| Market cap as of 2026-07-23 | $421M | $1.8B | |
| P/E as of 2026-07-23 | n/a | 247.97 | |
| Net margin as of 2026-07-23 | -281.6% | -0.8% | VERX higher |
| Gross margin as of 2026-07-23 | n/a | +64.3% | |
| Operating margin as of 2026-07-23 | -281.3% | -1.7% | VERX higher |
| ROE as of 2026-07-23 | -677.4% | -2.5% | VERX higher |
| ROA as of 2026-07-23 | -58.3% | -0.5% | VERX higher |
| Debt / equity as of 2026-07-23 | 12.40 | 1.37 | VERX lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.0% | +11.8% | VERX higher |
| Revenue CAGR (3y) SEC XBRL | +27.1% | +15.0% | EDIT higher |
| Dividend streak (yrs) SEC XBRL | n/a | 3 | |
| Beta as of 2026-07-23 | 2.08 | 0.84 | |
| 1-year return as of 2026-07-22 close | -8.3% | -68.7% | EDIT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.